LAUSR

Proteomics is inviting submissions to a special issue on singlecell multiomics for immuno-oncology and cancer systems biology. This issue is tentatively scheduled for publication in spring/summer 2020. Recent advances in cancer immunotherapies have provided paradigm shifts in treating patients with advanced malignancies. The development and therapeutic use of various immunotherapy regimens rely on the systems-level understanding of cellular composition, interaction, and dynamics of the tumor ecosystem.[1] Tumors are infiltrated with immune, stromal, and other cell types, leading to extraordinary intratumor heterogeneity, which plays a vital role in tumor progression and requires new methods such as single-cell multiomics approaches and systems-level analysis to tackle. The objective of this special issue is to cover a variety of emergent single-cell omics technologies and showcase their applications in immuno-oncology and cancer systems biology, aiming at highlighting the synergy of these two exciting and fast-evolving fields. We welcome manuscripts from all related areas of single-cell omics and cancer systems biology. The types of manuscripts such as research articles, review articles, technical briefs, dataset briefs, and viewpoint articles will all be considered. A suite of toolkits that permit the analysis of single-cell variability in different classes of biomolecules, including genome, epigenome, transcriptome, proteome, and metabolome, have been developed at a lightning pace.[2] Tools for simultaneous quantification of multiple omics from the same single cells also emerge in the last couple of years. Such measurements significantly improve our understanding of the extent, cause, and consequences of cellular heterogeneity in cancer and allow researchers to ask questions from perspectives previously unattainable. Importantly, single-cell multiomics are moving toward the clinical arena with more and more exciting translational and clinical applications demonstrated, as exemplified by immuno-oncology.[3]